glp-1 agonist prediabetes Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements GLP-1 Receptor Agonists | New

Liraglutide (Saxenda), administered as a daily 3.0 mg subcutaneous injection, was the first GLP-1 agonist approved specifically for weight management and produces average weight loss of 5-10% in clinical trials

This necessity limits accessibility and increases the cost, making it less feasible for continuous use

Current therapeutic strategies mitigate these complications by increasing the concentration of RBCs with normal hemoglobin via transfusion, inducing fetal hemoglobin, restoring nitric oxide signaling, inhibiting platelet-endothelium interaction, and stabilizing hemoglobin in its oxygenated state

Sulforaphane improves abnormal lipid metabolism via both ERS-dependent XBP1/ACC &SCD1 and ERS-independent SREBP/FAS pathways

10.1016/j.tiv.2020.104987 95 RinaldiC.SchmidtT.SituA